## Drug Summary
Morphine glucuronide, specifically morphine-6-glucuronide (M6G), is an active metabolite of morphine primarily used in the research setting for the treatment of acute and chronic pain. M6G is produced through the liver's metabolic processing of morphine. Although the complete pharmacodynamics of M6G are not fully elucidated, it is known to act similarly to morphine by targeting opioid receptors in the central nervous system (CNS). These receptors are critically involved in expressing the analgesic effects of opioids. M6G is believed to have a slightly modified receptor affinity compared to morphine, which suggests potential variations in its analgesic efficacy and side effect profile, particularly regarding respiratory depression. 

## Drug Targets, Enzymes, Transporters, and Carriers
M6G primarily interacts with opioid receptors in the human body. These include the mu-type opioid receptor (OPRM1), where it shows a significant binding affinity, potentially even greater than that of morphine. It also interacts with the delta-type (OPRD1) and kappa-type (OPRK1) opioid receptors, whereby it generally exhibits lower affinity compared to mu-type. These receptors facilitate its analgesic and potential respiratory depressive actions. Specific binding differences at subtypes of these receptors (e.g., mu1 vs. mu2) are under study to understand better the differential effects of M6G compared to its parent compound, morphine. There is no detailed information on specific enzymes, transporters, or carriers involved in the metabolism or transport of M6G.

## Pharmacogenetics
The pharmacogenetics of M6G revolves significantly around its metabolism from morphine, where genetic variations can influence M6G's formation and consequently its clinical effects. The pharmacogenetics primarily concern morphine processing enzymes such as UGT2B7, which glucuronidates morphine to form M6G. Variations in UGT2B7 activity due to genetic polymorphisms might affect the levels and effectiveness of M6G, altering pain control outcomes or side effect profiles. There are no specific genomic data provided for direct associations with M6G; however, understanding the genetic basis in morphine metabolism can indirectly inform about variations in M6G's pharmacokinetics and pharmacodynamics. Further genetic investigations and clinical correlation studies are needed to elaborate the precise pharmacogenetic impacts on M6G efficacy and safety.